NEW YORK (GenomeWeb) – Abbott reported Wednesday morning that first quarter sales in its Diagnostics business grew 4 percent year over year, driven by strong growth in core laboratory and point-of-care sales.

For the three months ended March 31, Abbott reported overall Q1 revenues of $6.34 billion, up 30 percent on a reported basis from Q1 last year, and up 3 percent on a comparable basis accounting for the acquisition of St. Jude Medical closed in January. The company beat the consensus Wall Street estimate of $6.15 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.